Steven Cohen Moon Lake Immunotherapeutics Transaction History
Point72 Asset Management, L.P.
- $42.2 Billion
- Q4 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 98,719 shares of MLTX stock, worth $4.23 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
98,719Holding current value
$4.23 Million% of portfolio
0.01%Shares
3 transactions
Others Institutions Holding MLTX
# of Institutions
136Shares Held
58.1MCall Options Held
124KPut Options Held
96.9K-
Bvf Inc San Francisco, CA19.8MShares$846 Million39.28% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$364 Million35.64% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.34MShares$143 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$119 Million2.15% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.19MShares$93.7 Million0.02% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.58B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...